 <h1>Ibalizumab Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to ibalizumab: intravenous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, ibalizumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking ibalizumab:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Back pain</li>
<li>blurred vision</li>
<li>confusion</li>
<li>dizziness</li>
<li>drowsiness</li>
<li>fever</li>
<li>headache</li>
<li>seizures</li>
<li>severe rash</li>
<li>unusual tiredness or weakness</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of ibalizumab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Diarrhea</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Nausea</li>
<li>rash</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ibalizumab: intravenous solution</i></p><h3>General</h3><p>The primary safety assessment was based on 24 weeks of data from a trial which enrolled 40 heavily therapy-experienced patients with multidrug-resistant HIV-1 on a failing HIV treatment regimen.  The most common side effects reported were diarrhea, dizziness, nausea, and rash.  Most side effects were mild or moderate in severity.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased creatinine (10%)<sup>[Ref]</sup></p><p>Increased creatinine (greater than 1.8 times the upper limit of normal [1.8 x ULN] or 1.5 times baseline) has been reported in 10% of patients.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Increased lipase (greater than 3 x ULN) has been reported in 5% of patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Diarrhea, nausea, increased lipase<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dizziness<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash (included rash, erythematous rash, generalized rash, macular rash, maculopapular rash, papular rash)<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Decreased leukocytes (less than 1.5 x 10[9] cells/L), neutrophils (less than 0.6 x 10[9] cells/L), hemoglobin (less than 8.5 g/dL), and platelets (less than 50,000/mm3) have been reported in 5%, 5%, 3%, and 3% of patients, respectively.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Decreased leukocytes, decreased neutrophils, decreased hemoglobin, decreased platelets<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased bilirubin, increased direct bilirubin<sup>[Ref]</sup></p><p>Increased bilirubin (at least 2.6 x ULN) and direct bilirubin (greater than ULN) have been reported in 5% and 3% of patients, respectively.<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Increased blood glucose (greater than 250 mg/dL) and uric acid (greater than 12 mg/dL) have each been reported in 3% of patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Increased blood glucose, increased uric acid<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Immune reconstitution inflammatory syndrome (manifested as exacerbation of progressive multifocal leukoencephalopathy), positive test for anti-ibalizumab antibodies<sup>[Ref]</sup></p><p>All patients enrolled in the clinical trials were tested for anti-ibalizumab antibodies during their participation; 1 sample tested positive with low titer anti-ibalizumab antibodies.  No side effect or reduced efficacy was attributed to the positive sample reported in this patient.<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Trogarzo (ibalizumab)." Theratechnologies Inc., Montreal, ON. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>How well does Trogarzo work to treat multidrug-resistant (MDR) HIV-1?</li>
<li>How is Trogarzo used in the treatment of HIV?</li>
<li>What are the side effects with HIV treatment Trogarzo?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about ibalizumab</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>En Espa√±ol</li>
<li>Drug class: miscellaneous antivirals</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ibalizumab-uiyk Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Trogarzo</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>HIV Infection</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ibalizumab: intravenous solution</i></p><h3>General</h3><p>The primary safety assessment was based on 24 weeks of data from a trial which enrolled 40 heavily therapy-experienced patients with multidrug-resistant HIV-1 on a failing HIV treatment regimen.  The most common side effects reported were diarrhea, dizziness, nausea, and rash.  Most side effects were mild or moderate in severity.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased creatinine (10%)<sup>[Ref]</sup></p><p>Increased creatinine (greater than 1.8 times the upper limit of normal [1.8 x ULN] or 1.5 times baseline) has been reported in 10% of patients.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Increased lipase (greater than 3 x ULN) has been reported in 5% of patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Diarrhea, nausea, increased lipase<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dizziness<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash (included rash, erythematous rash, generalized rash, macular rash, maculopapular rash, papular rash)<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Decreased leukocytes (less than 1.5 x 10[9] cells/L), neutrophils (less than 0.6 x 10[9] cells/L), hemoglobin (less than 8.5 g/dL), and platelets (less than 50,000/mm3) have been reported in 5%, 5%, 3%, and 3% of patients, respectively.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Decreased leukocytes, decreased neutrophils, decreased hemoglobin, decreased platelets<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased bilirubin, increased direct bilirubin<sup>[Ref]</sup></p><p>Increased bilirubin (at least 2.6 x ULN) and direct bilirubin (greater than ULN) have been reported in 5% and 3% of patients, respectively.<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Increased blood glucose (greater than 250 mg/dL) and uric acid (greater than 12 mg/dL) have each been reported in 3% of patients.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Increased blood glucose, increased uric acid<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Immune reconstitution inflammatory syndrome (manifested as exacerbation of progressive multifocal leukoencephalopathy), positive test for anti-ibalizumab antibodies<sup>[Ref]</sup></p><p>All patients enrolled in the clinical trials were tested for anti-ibalizumab antibodies during their participation; 1 sample tested positive with low titer anti-ibalizumab antibodies.  No side effect or reduced efficacy was attributed to the positive sample reported in this patient.<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Trogarzo (ibalizumab)." Theratechnologies Inc., Montreal, ON. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>How well does Trogarzo work to treat multidrug-resistant (MDR) HIV-1?</li>
<li>How is Trogarzo used in the treatment of HIV?</li>
<li>What are the side effects with HIV treatment Trogarzo?</li>
</ul><h2>More about ibalizumab</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>En Espa√±ol</li>
<li>Drug class: miscellaneous antivirals</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ibalizumab-uiyk Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>HIV Infection</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>